Newsflash

LIFT Cancer Trial Starting in China
A new clinical trial based on Dr. Zheng Cui's granulocyte technology is starting at Beijing's 304 Hospital. Go to The LIFT Cancer Treatment Trial Site for more information.
Prostate Cancer Treatment Print

Prostate cancer is the second most common cancer in men. Though the five year survival rate is relatively high, prostate cancer is still the second cause of cancer related death after lung cancer for men in many western countries.

The treatment plan is developed from one’s age, general health condition, stage, and grade of cancer and side effects with treatment. Expectant management or watchful waiting is recommended if the patient is old or has other serious health condition and if the tumor is localized and has no symptoms since prostate cancer often grows very slowly. If the prostate tumor grows more quickly or causes symptoms, active treatments will be suggested.

Traditional Treatments include Surgery, Radiotherapy, Chemotherapy, and Hormone Therapy

Cutting-edge therapies available in China Cancer Centers (CCC) for prostate cancer may consist some of:
For early stage prostate cancer,
    Surgery
    Hormone therapy
    CIK-DC immunotherapy

Features:
    1. Efficient prevention of recurrence and metastasis
    2. Good quality of life

For advanced prostate cancer,
    Cryoablation
    Gentle chemotherapy
    Gene therapy
    Antiangionesis therapy
    Hormone therapy
    CIK-DC cell immunotherapy

 Features:
    1. Low toxicity or side effects to human body.
    2. Minimally invasive cryoablation, with little harm to normal function and little pains to patients, small incision and quick recovery.
    3. Significantly extends survival time with a good quality of life

Last Updated on Tuesday, 18 August 2009 12:12